Peter Lobo, MD Lab
Professor of Medicine, Medicine: Nephrology
UVA Division of Nephrology
PO Box 800133
Charlottesville, VA 22908
EDUCATION AND TRAINING
- Fellowship, Nephrology, Immunology, Transplantation, University of Virginia
- MD, Makerere University
- Residency, Makerere University
Basic Transplant Immunology; Role of Naturally occurring IgM antibodies in Acute Kidney Injury and transplant rejection.
CURRENT LABORATORY MEMBERS
Dr. Sylvia Cechova received her undergraduate degree in Nuclear Chemistry as well as her graduate Ph.D. degree in Radiation Chemistry from Comenius University in Bratislava, Slovakia. She conducted postdoctoral research in the Department of Anesthesiology and in the Department of Chemistry, University of Virginia, to study the effect of drugs and anesthetics on the threshold for isoflurane anesthesia and to study the transient release of adenosine and dopamine in rat brain in vivo, using fast-scan voltammetry with a carbon-fiber microelectrode, respectively. She joined the Department of Medicine, Division of Nephrology, in August 2013 to work with Dr. Thu Le on a project that focused on identifying genes associated with hypertension. Especially they were interested in GSTM1 and Collectrin genes and how their deletion or modification of them will affect the development of hypertension and the progression of kidney disease and its cardiovascular consequences. After the last two years in Dr. Swaminatan Lab, where she focused on the roles of hepcidin, ferroptosis, and macrophage iron metabolism in the progression of chronic kidney disease and renal fibrosis, she joined the Dr. Okusa and Dr. Lobo labs in May 2020. Her current research focuses on the sphingolipid pathway’s contribution to the prevention or attenuation of fibrosis following AKI and the role of natural IgM upregulation in the recovery after AKI.
Lab Team Images
My primary research investigates the role of naturally occurring IgM autoantibodies that bind to receptors on inflammatory and endothelial cells. Thus far, we have shown that these antibodies regulate inflammatory cell functions and downregulate the inflammatory response that occurs after acute ischemic injury to the kidney and after transplantation (i.e. rejection). A subset of normal individuals and patients awaiting transplantation (i.e. kidney, heart) have high levels of these natural antibodies. We and others have noted a strong association between the presence of elevated IgM anti-leukocyte natural antibodies and protection from rejection.
Currently, our primary research efforts are focused on 1) studying the mechanism by which IgM downregulates the inflammatory response; 2) determining if there is a role of IgM in inducing transplant tolerance, thus decreasing the use of immunosuppressive agents; and 3) evaluating strategies (e.g. vaccines) to increase levels of such antibodies, especially in patients awaiting transplantation. Other clinical studies aim to determine if there is an association between levels of such antibodies and the severity of renal failure (e.g. after cardiac surgery) and severity of glomerular inflammation (e.g. in SLE or IgA nephropathy).
My clinical research involves transplant immunobiology, primarily focusing on B cell regulation, alloantibodies, and desensitizing patients with donor-specific antibodies.